Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Receives Consensus Recommendation of “Hold” from Analysts

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) has earned an average rating of “Hold” from the eleven analysts that are currently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, four have issued a hold rating and six have issued a buy rating on the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $39.4444.

Several equities research analysts have weighed in on AGIO shares. The Goldman Sachs Group cut their target price on shares of Agios Pharmaceuticals from $40.00 to $25.00 and set a “neutral” rating on the stock in a report on Thursday, November 20th. Citigroup reaffirmed a “buy” rating on shares of Agios Pharmaceuticals in a research note on Friday, December 26th. Truist Financial lifted their target price on Agios Pharmaceuticals from $32.00 to $38.00 and gave the stock a “buy” rating in a report on Wednesday, December 24th. Royal Bank Of Canada downgraded Agios Pharmaceuticals from an “outperform” rating to a “sector perform” rating and lowered their price target for the stock from $57.00 to $28.00 in a report on Wednesday, November 19th. Finally, Wall Street Zen cut Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, November 22nd.

Insider Activity

In other Agios Pharmaceuticals news, CEO Brian Goff sold 18,703 shares of Agios Pharmaceuticals stock in a transaction that occurred on Tuesday, December 30th. The shares were sold at an average price of $27.09, for a total value of $506,664.27. Following the transaction, the chief executive officer owned 136,583 shares of the company’s stock, valued at approximately $3,700,033.47. The trade was a 12.04% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO Cecilia Jones sold 2,932 shares of the stock in a transaction on Tuesday, December 30th. The stock was sold at an average price of $27.09, for a total transaction of $79,427.88. Following the sale, the chief financial officer directly owned 37,394 shares of the company’s stock, valued at $1,013,003.46. This represents a 7.27% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 33,503 shares of company stock worth $910,745. Corporate insiders own 4.93% of the company’s stock.

Institutional Trading of Agios Pharmaceuticals

Several hedge funds and other institutional investors have recently modified their holdings of AGIO. Assetmark Inc. boosted its position in shares of Agios Pharmaceuticals by 37.9% during the fourth quarter. Assetmark Inc. now owns 1,317 shares of the biopharmaceutical company’s stock worth $36,000 after buying an additional 362 shares during the period. NewEdge Advisors LLC bought a new stake in Agios Pharmaceuticals in the 1st quarter valued at approximately $40,000. First Horizon Corp acquired a new position in Agios Pharmaceuticals during the 3rd quarter worth approximately $45,000. Mirae Asset Global Investments Co. Ltd. boosted its position in Agios Pharmaceuticals by 16.7% during the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,237 shares of the biopharmaceutical company’s stock worth $74,000 after acquiring an additional 320 shares during the last quarter. Finally, Quantbot Technologies LP acquired a new stake in shares of Agios Pharmaceuticals in the third quarter valued at approximately $79,000.

Agios Pharmaceuticals Trading Down 0.2%

Shares of AGIO opened at $26.53 on Monday. The stock has a market cap of $1.55 billion, a P/E ratio of -3.79 and a beta of 0.91. Agios Pharmaceuticals has a 1 year low of $22.24 and a 1 year high of $46.00. The stock’s 50-day moving average price is $27.38 and its two-hundred day moving average price is $34.40.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company’s scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.

Agios’s lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.